The ADAURA study is a clinical study aimed at evaluating the adjuvant therapy of osimertinib for patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) replacement mutation in stage IB-IIIA, and this article was personally published in future Oncology by a team of ADAURA research experts. The preliminary results of this study are summarized in plain language. Today Xiaobian will lead you to understand the ADAURA research to assist in the treatment of osimertinib.
ADAURA research significance: Adjuvant therapy with osimertinib can bring clinical benefit to patients with complete resection of EGFR-sensitive mutation positive (EGFRm) NSCLC, and has been approved for adjuvant therapy after complete resection of stage IB-IIIA EGFRm NSCLC.
Current data suggest that patients with stage IB-IIIA EGFRm NSCLC who take osiminib have a longer tumor-free survival after surgical resection of a tumor
Regardless of whether chemotherapy has been received postoperatively, treatment with osimertinib prolongs tumor-free survival
Oscitinib treatment also reduces the risk of recurrence or death in the central nervous system (CNS).
The side effects of osimtinib are consistent with previously known side effects, and the number of patients who discontinue treatment due to side effects is small
ADAURA Study Design and Purpose:
To assess the benefits and safety of adjuvant therapy with osimtinib
Results of osimertinib were compared with placebo to assess tumor-free survival in completely resected EGFRm NSCLC (phase IB, II, or IIIA) subjects, and the safety of adjuvant targeted therapy was assessed.
ADAURA findings:
Subjects taking osimertinib had longer tumor-free survival
The clinical features of the subjects in both groups were similar.
In completely resected phase II-IIIA NSCLC subjects, subjects taking osiminib had an 83% lower risk of tumor recurrence or death compared to placebo.
In completely resected IB-IIIA stage NSCLC subjects, subjects taking osimertinib had an 80% lower risk of tumor recurrence or death compared to placebo.
Regardless of whether they had previously received postoperative chemotherapy, 89% of subjects taking osimtinib were still alive and tumor-free for 2 years.
Treatment with ositinib also reduces the risk of CNS recurrence.
Subjects taking osimtinib had an 82 percent lower risk of CNS recurrence or death
Of all completely resected NSCLC subjects, only 1 percent of subjects taking osimertinib experienced a CNS recurrence, compared to 10 percent in the placebo group.
The observed side effects are consistent with previously known side effects of osimertinib.
bibliography:
1.Wu YL, Herbst RS, et al. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncol. 2021 Dec 1;17(35):4827-4835.
*This information is for medical and scientific exchange by medical and health professionals only and is not intended for promotional purposes.
Approval number CN-89641 Expires 2022-12-16
Source: Medical community
Editor-in-charge: Zheng Huaju
Proofreader: Zang Hengjia
Plate making: Xue Jiao